Servier and its American subsidiary Servier Pharmaceuticals will present data from multiple studies at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando (USA), from December 7-10, 2019.
With more than 17,000 members from nearly 100 countries, ASH is the world’s largest professional society serving both clinicians and scientists who are working to conquer blood diseases.
“As a patient-centric, innovation-driven organization, we believe it is critical to foster scientific exchange and discussion around novel approaches to treating hematologic-oncologic conditions and addressing unmet needs,” said Claude Bertrand, Executive Vice President of Research and Development, Servier Group. “Oncology is one of Servier’s strategic priorities and these new data findings to be presented at ASH 2019 demonstrate our expanding pipeline of drug candidates, including allogeneic CAR-T therapy.”
— ASH (@ASH_hematology) December 4, 2019
Did you know?
More than 40 percent of Servier Group’s investments in R&D are devoted to fighting cancer. Servier’s research in oncology focuses on therapies aimed at restoring programmed cell death (apoptosis) in cancer cells and at mobilizing the immune system against cancer cells (immuno-oncology).